Esperion to Participate in Bank of America Securities 2023 Health Care Conference
27. April 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 27, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America...
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
25. April 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on...
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
19. April 2023 08:42 ET
|
Esperion Therapeutics, Inc.
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales...
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
03. April 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd...
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22. März 2023 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an...
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20. März 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused...
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
08. März 2023 08:00 ET
|
Esperion Therapeutics, Inc.
– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – ...
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
04. März 2023 10:30 ET
|
Esperion Therapeutics, Inc.
– NEXLETOL Significantly Reduced Risk of Major Adverse Cardiovascular Events (MACE-4) and (MACE-3) by 13% (P=0.004) and 15% (P=0.006), Respectively, and Significantly Reduced Risk of Myocardial...
Esperion Launches New Scientific Website
24. Februar 2023 13:40 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 24, 2023 (GLOBE NEWSWIRE) -- With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared...
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
23. Februar 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Sheldon Koenig, president and chief executive officer, will present at Cowen’s 43rd annual Health...